An article titled, “Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?” was published in Diabetes Spectrum by authors Sun H. Kim, Gavin Hui, C. William Pike, Michael L. Jackson, Marcie Levine, and Paul Kwo. Dr. Hui and Dr. Pike and Mr. Jackson are affiliated with Atropos Health. Dr. Kim, Dr. Levine, and Dr. Kwo are affiliated with Stanford University.
Short Summary:
Patients with type 2 diabetes are at an elevated risk for metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis. Multiple professional societies recommend initiating screening with a fibrosis-4 (FIB-4) index score calculation. This study aimed to evaluate the frequency of laboratory assessments necessary for FIB-4 score calculation in patients with type 2 diabetes. Our findings indicate that, although testing frequency for liver health in patients with type 2 diabetes is gradually increasing, substantial gaps in clinical practice persist.